Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells
DOI: https://doi.org/10.2147/ijn.s445101
IF: 7.033
2024-03-18
International Journal of Nanomedicine
Abstract:Dong Hu, 1 Ruyue Yang, 1 Guidan Wang, 2 Hao Li, 1 Xulong Fan, 1 Gaofeng Liang 1 1 School of Basic Medicine and Forensic Medicine, Henan University of Science & Technology, Luoyang, 471023, People's Republic of China; 2 School of Medical Technology and Engineering, Henan University of Science & Technology, Luoyang, 471023, People's Republic of China Correspondence: Gaofeng Liang, School of Basic Medicine and Forensic Medicine, Henan University of Science & Technology, Luoyang, 471023, People's Republic of China, Email Adoptive T cells immunotherapy, specifically chimeric antigen receptor T cells (CAR-T), has shown promising therapeutic efficacy in the treatment of hematologic malignancies. As extensive research on CAR-T therapies has been conducted, various challenges have emerged that significantly hampered their clinical application, including tumor recurrence, CAR-T cell exhaustion, and cytokine release syndrome (CRS). To overcome the hurdles of CAR-T therapy in clinical treatment, cell-free emerging therapies based on exosomes derived from CAR-T cells have been developed as an effective and promising alternative approach. In this review, we present CAR-T cell-based therapies for the treatment of tumors, including the features and benefits of CAR-T therapies, the limitations that exist in this field, and the measures taken to overcome them. Furthermore, we discuss the notable benefits of utilizing exosomes released from CAR-T cells in tumor treatment and anticipate potential issues in clinical trials. Lastly, drawing from previous research on exosomes from CAR-T cells and the characteristics of exosomes, we propose strategies to overcome these restrictions. Additionally, the review discusses the plight in large-scale preparation of exosome and provides potential solutions for future clinical applications. Keywords: tumor, CAR-T cells, immune escape, exosome CAR-T therapy represents tremendous progress in the field of tumor treatment. 1–4 After tight binding of the tumor target antigen to the single-chain variable fragment (scFv) of the specific antibody in the extracellular binding domain, the signal is transmitted through the hinge region, the transmembrane structural domain, to the intracellular structural domain and subsequently initiates activation in the T cells. Notably, the intracellular signaling domain is the initial signal for T cells activation, whereas intracellular co-stimulatory domains such as CD28/4-1BB are integral to the sustained activation and proliferation of T cells (Figure 1). 5 Six CAR-T-related drugs, all of which target hematologic cancers, have been approved for commercialization by the Food and Drug Administration (FDA) to date. 6 CAR-T therapy for solid tumors has been encouraged by the success of CAR-T therapy for hematological cancers. With the development of this field, many CAR therapies based on a variety of other immune cells have emerged, such as CAR-NK and CAR-M. However, despite the fact that current scientists have developed strategies and achieved remarkable remission results, there are a number of obstacles in solid tumors, such as the difficulty in infiltrating the solid tumors, T-cell exhaustion, and CRS, that have not been addressed at their root. 7,8 The advent of CAR-T cell-derived exosomes offers a promising prospect for the treatment of malignancies, with the benefits of nanoscale size and cell-free nature compensating for the drawbacks of treating solid tumors and so attaining considerable remission (Figure 2). 9 Most of the exosomes from CAR-T cells, which possess the properties of the parental cells, including CAR, CD3, granzyme, perforin, etc., also show promising anti-tumor effects in in vitro experiments and preclinical models and are promising to become an additional option for the treatment of tumor patients. 9,10 In this review, we introduce the significant benefits of CAR-T therapy in treating tumors, discuss the limitations of the therapy and the corresponding mechanisms, and finally highlight the superior potential of exosomes from CAR-T cells in the field of tumor treatment. Figure 1 Schematic diagram of a standard second-generation CAR-T cell structure. A chimeric antigen receptor (CAR) has a heavy chain variable region (VH) and a light chain variable region (VL) in the sequence of an antibody against a target antigen. The hinge region links the transmembrane domain to the intracellular co-stimulatory domain and the CD3 signaling domain. If the scFv identifies the target antigen, it stimulates the signaling and co-stimulatory domains in order to promote sustained T cell proliferation and effector functions. Figure 2 Biogenesis and killing mechanisms of -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology